Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.68 |
| ▸ | BACE1 | P56817 | 9/20 | 0.68 |
| ▸ | BCHE | P06276 | 6/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186709 | 0.98 | ACHE (0.66) | ACHEBACE1BCHECXCR4MEN1 | |
| SCHEMBL28169202 | 0.91 | CXCR4 (0.68) | ACHEBACE1BCHECXCR4MEN1 | |
| SCHEMBL8228694 | 0.85 | BCHE (0.57) | ACHEBACE1BCHECXCR4MEN1 | |
| SCHEMBL8576045 | 0.85 | BCHE (0.73) | ACHEBACE1BCHECXCR4 | |
| SCHEMBL20183336 | 0.85 | BCHE (0.73) | ACHEBACE1BCHECXCR4 | |
| SCHEMBL31014995 | 0.83 | BCHE (0.58) | ACHEBACE1BCHEKDM1AMAOB | |
| SCHEMBL9437321 | 0.82 | ACHE (0.60) | ACHEBACE1BCHECXCR4MEN1 | |
| SCHEMBL31014655 | 0.81 | BCHE (0.61) | ACHEBACE1BCHEMAOB | |
| SCHEMBL14367985 | 0.81 | ACHE (1.00) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL8408423 | 0.81 | ACHE (0.66) | ACHEBACE1BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACHE 1031/4885BACE1 319/4885BCHE 2131/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACHE 1031/4885BACE1 319/4885BCHE 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.